Direct Compression as the Preferred Route for 5 mg and 10 mg Monolithic Tablets

When benazepril hydrochloride pharmaceutical-grade active pharmaceutical ingredient is selected for an immediate-release monolithic tablet, direct compression remains the primary processing route because the ethyl ester side chain is susceptible to hydrolytic cleavage to benazeprilat under aqueous granulation conditions. The API is passed through a 20 mesh (840 μm) stainless steel screen with a delumping device, then blended with lactose monohydrate (USP, Ph.Eur.) and microcrystalline cellulose (USP) in a bin blender at 15 rpm for 20 min. Crospovidone (USP) at 2.0%–5.0% w/w is used as disintegrant; colloidal silicon dioxide (USP) at 0.25%–0.50% w/w is added to improve powder flow. Magnesium stearate (USP) is added last at 0.5%–1.0% w/w and blended for 3–5 min to avoid over-lubrication. Blend uniformity is assessed according to FDA 21 CFR 211.110 and current FDA guidance, with acceptance mean 90.0%–110.0% and RSD ≤5.0%. Compression is performed on a rotary tablet press with precompression force 5–8 kN and main compression force 12–18 kN, targeting tablet hardness 60–90 N and friability <0.8% per USP <1216>. The finished tablet assay acceptance range is 90.0%–110.0% of label claim; individual content uniformity is evaluated by USP <905> with acceptance value L1 ≤15.0. Dissolution is run in 900 mL degassed water at 37°C ± 0.5°C using USP <711> Apparatus 2 at 50 rpm, with the product requirement of not less than 80% dissolved at 30 min where the USP tablet monograph is applicable. Primary packaging in 45 mL HDPE bottles with heat-sealed foil induction liners and a 1 g silica gel desiccant canister limits moisture ingress.

Hard gelatin capsule formats for benazepril hydrochloride present different powder flow and dust control constraints compared with monolithic tablets. The encapsulated blend is typically manufactured by geometric dilution of the API with lactose monohydrate (USP) and pregelatinized starch (USP) in a 600 L bin blender, followed by addition of crospovidone (USP) and talc (USP). Because the active is low-dose, content uniformity risk is managed by milling the API with 0.25% w/w colloidal silicon dioxide before blending; the blend acceptance criterion is mean 90.0%–110.0% with RSD ≤4.0% per USP <905> for the filled capsule. Encapsulation on a dosator-type capsule machine requires pins with 2–4 mm tamping compression depth, while tamping-type machines operate with tamping stations preset to 8–12 N and 1,500–3,000 capsules/min depending on size 3 or size 4 format. Moisture in the capsule shell is controlled to 13%–16% w/w because lower moisture embrittles the gelatin and higher moisture can promote API hydrolysis at the capsule wall interface; relative humidity in the encapsulation suite is maintained at 35%–45% RH. Capsule dissolution is evaluated by USP <711>; if the capsule is not covered by a dedicated USP monograph, a method transfer from the tablet monograph is justified only when equivalent dissolution profiles in water, 0.1 N HCl, and pH 4.5 acetate buffer are demonstrated with f2 value ≥50. Terminal packaging in PVC/PVDC/aluminum blisters with 40 g/m² PVDC coating is used to reduce moisture ingress under ICH stability conditions at 25°C ± 2°C / 60% RH ± 5% RH.

Aqueous film coating of benazepril hydrochloride tablets introduces a controlled moisture load that must be removed before the tablet core temperature exceeds 45°C. The coating pan is operated with a 36-inch perforated drum at 6–10 rpm, a spray rate of 80–150 g/min per gun, atomizing air pressure 1.0–2.0 bar, and inlet air temperature 55°C–65°C. Bed temperature is maintained at 38°C–42°C and outlet air temperature at 30°C–35°C; exhaust humidity is held below 10 g/m³ to ensure rapid evaporation. A ready-to-use polyvinyl alcohol-based coating system compliant with USP/NF is dispersed in purified water at 12%–15% w/w solids. The target weight gain is 3%–5% for immediate-release tablets; higher weight gain prolongs disintegration time without measurable stability benefit. Coated tablets are dried in the pan for 10 min after spraying, then transferred to a tray dryer at 40°C for 30 min until residual moisture content is ≤2.0%. Because benazepril hydrochloride is an ethyl ester prodrug, aqueous coating can generate localized moisture gradients at the core surface; therefore the coating dispersion is applied only after the core reaches 38°C and not to cold cores. Dissolution after coating is rerun with USP <711>; the release profile is compared with the uncoated core and f2 value ≥50 is required to show equivalent release.

Which Process Limits Are Dictated by Benazepril Hydrochloride Hydrolysis During Wet Granulation?

Wet granulation of benazepril hydrochloride is technically possible but is constrained by the hydrolytic lability of the ethyl ester side chain in aqueous media. In a high-shear granulator with an impeller speed of 150–300 rpm and chopper speed of 1,500–3,000 rpm, water is typically added at 10%–20% w/w; however, exposure to free water at granulation bowl temperatures above 50°C accelerates the formation of benazeprilat and lactam-related degradation products. Published quantitative kinetic data for benazepril hydrochloride under specific high-shear wet granulation conditions is limited; therefore, the practical approach is to limit water volume to ≤8% w/w by using a binder solution of povidone (USP) in 50% v/v ethanol/water, which depresses water activity and reduces hydrolysis. The wet mass is dried in a fluid-bed dryer with inlet air temperature 40°C–45°C and product temperature 28°C–32°C until loss on drying is ≤1.5%. Drying time above 90 min is avoided because extended exposure to residual moisture at elevated temperature raises total degradation products. If granulation is unavoidable due to particle size or dose uniformity requirements, dry granulation by roller compaction is generally preferred over wet massing because it eliminates aqueous hydrolysis and shortens processing time.

Roller compaction converts benazepril hydrochloride, microcrystalline cellulose (USP), croscarmellose sodium (USP), and magnesium stearate (USP) into free-flowing granules without introducing water. The API is preblended with 50% of the intragranular excipients in a V-blender for 15 min, then passed through a roller compactor with roll pressure 30–60 bar, roll speed 2–6 rpm, and gap 1.0–2.0 mm. The resulting ribbons are milled through a 1.0 mm screen with rotor speed 500–1,200 rpm, producing granules with 60%–80% retained between 180 μm and 500 μm. Ribbon density is monitored to 1.0–1.3 g/cm³; lower density produces excessive fines and poor flow, while higher density reduces tablet compressibility and leads to capping. The extragranular portion consists of croscarmellose sodium (USP) at 2.0%–4.0% w/w and silicon dioxide (USP) at 0.25%–0.50% w/w, blended for 5 min. Tablets compressed from dry granulation typically show hardness 70–100 N, friability <0.5%, and disintegration time <5 min in 900 mL water at 37°C ± 0.5°C per USP <701>. Dissolution acceptance follows USP <711> with the same apparatus and medium as the direct compression tablets. The dry granulation route is especially advantageous when API particle size distribution is irregular and direct compression cannot deliver content uniformity; roller compaction narrows the API distribution by adhering fine particles to larger excipient particles, thus improving blend homogeneity.

If Aseptic Filtration Replaces Terminal Sterilization for an Investigational Injectable

Injectable benazepril hydrochloride is not described in a current USP or EP product monograph; published data for this specific configuration is limited. Nevertheless, if a parenteral presentation is developed, the formulation strategy must account for the hydrolytic instability of the ethyl ester group in aqueous solution. The drug solution can be prepared in Water for Injection (USP) with pH adjusted to 3.5–4.5 using 0.1 N hydrochloric acid or 0.1 N sodium hydroxide; at pH ≥5.0, ester hydrolysis to benazeprilat increases rapidly, while at pH <3.0, acid-catalyzed lactamization becomes a risk. Terminal sterilization by autoclaving at 121°C for 15 min generally produces unacceptable degradation and is replaced by aseptic filtration through a validated 0.22 μm polyvinylidene fluoride or polyethersulfone membrane under ISO 13408-2 aseptic processing conditions. Tonicity is adjusted with sodium chloride (USP) to 280–320 mOsm/kg; if the API solubility in the selected vehicle is insufficient to achieve the target concentration, published data for the specific configuration is limited and solubility enhancement studies are required. The filled containers are closed with chlorobutyl rubber stoppers meeting USP <381> and stored at 2°C–8°C; freeze-drying is preferred if an aqueous formulation fails stability due to hydrolysis. A lyophilized presentation would require lyoprotectants such as mannitol (USP) at 2.0%–5.0% w/v, with reconstitution to 5–10 mL Water for Injection immediately before use. Sterility is tested by USP <71>, bacterial endotoxins by USP <85> with limit ≤0.25 EU/mg where a parenteral monograph is assigned, particulate matter by USP <788>, and leachables by USP <1664>. Because benazepril is a prodrug requiring hepatic esterase activation, the pharmacodynamic onset from an injectable route would differ from oral administration; this route is therefore investigational rather than established in clinical practice.

Granulated presentations for benazepril hydrochloride are most commonly dry-granulated materials filled into unit-dose sachets or bulk containers for suspension compounding. In a sachet format, the granule is prepared by roller compaction or dry blending of API with mannitol (USP), xylitol (USP), citric acid (USP), and sodium citrate dihydrate (USP) to provide a buffered pH 4.0–5.0 upon reconstitution. The granule is filled by auger or volumetric filler to a target fill weight variation of ±5%; fill weight is adjusted to deliver 5 mg, 10 mg, or 20 mg per sachet. Granule particle size is controlled between 150 μm and 710 μm; material below 150 μm is limited to ≤10% to minimize dust and static adhesion. The sachet film is a PET12/Alu9/PE60 laminate with water vapour transmission rate <0.1 g/m²/day at 38°C/90% RH, and a 1 g silica gel desiccant pouch is included where required. On reconstitution in 30 mL water, the dispersion is administered immediately; holding the dispersion for more than 2 h at room temperature is not recommended because benazepril hydrochloride shows pH-dependent hydrolytic degradation in aqueous media. If the product is intended for a hospital extemporaneous compounding setting, compliance with USP <795> for non-sterile compounding and FDA 21 CFR 210/211 for current good manufacturing practice is defined within the site quality agreement. Dissolution testing of granule-filled sachets uses USP <711> with the same paddle conditions as tablets, but the test is performed on the as-filled granule rather than a compressed tablet, and acceptance criteria must be justified by the applicant because no dedicated USP granule monograph exists.